New monoclonal antibody for thyroid eye disease

New monoclonal antibody for thyroid eye disease
Roibeard O’hEineachain
Roibeard O’hEineachain
Published: Monday, September 28, 2020
David B Granet MD FACS FAAP FAAO
The introduction and FDA approval of the monoclonal antibody teprotumumab (Tepezza, Horizon Therapeutics) heralds a new era in the treatment of thyroid eye disease, said David B Granet, MD FACS FAAP FAAO, Shiley Eye Center, University of California, San Diego, US. “We used to say that in the future thyroid eye disease will be stopped with medication and not the scalpel. The future has arrived,” Dr Granet told the 2020 WSPOS Virtual Meeting. The human monoclonal antibody was approved for use in the United States in January 2020. It binds to the insulin-like growth factor 1 receptor (IGF-1R) and by doing so also inhibits thyroid-stimulating hormone (TSH). In this way it inhibits the inflammatory cascade thereby reducing oedema and glycosaminoglycan production. It is administered intravenously at a dosage of 20mg/kg in eight cyles over 24 weeks, Dr Granet noted. The FDA approved teprotumumab based on two randomised controlled studies showing a greater than 2.0mm reduction in proptosis in 71% and 83% of patients receiving the monoclonal antibody, compared to 20% and 10% of control patients. Dr Granet presented two case studies, one with active disease and the other with chronic disease, whose eyes in both cases returned to their normal state after completing eight cycles of treatment. “This is a game changer; however, there are side-effects and of course we have to pay attention to the teratogenicity of this in someone who might be pregnant. There may be relapses as well and it is expensive,” Dr Granet added.
Tags: thyroid eye disease
Latest Articles
Organising for Success

Professional and personal goals drive practice ownership and operational choices.

Read more...

Update on Astigmatism Analysis

Read more...

Is Frugal Innovation Possible in Ophthalmology?

Improving access through financially and environmentally sustainable innovation.

Read more...

From Concept to Clinic

Partnerships with academia and industry promote innovation.

Read more...

Making IOLs a More Personal Choice

Surgeons may prefer some IOLs for their patients, but what about for themselves?

Read more...

Need to Know: Higher-Order Aberrations and Polynomials

This first instalment in a tutorial series will discuss more on the measurement and clinical implications of HOAs.

Read more...

Never Go In Blind

Novel ophthalmic block simulator promises higher rates of confidence and competence in trainees.

Read more...

Simulators Benefit Surgeons and Patients

Helping young surgeons build confidence and expertise.

Read more...

How Many Surgeries Equal Surgical Proficiency?

Internet, labs, simulators, and assisting surgery all contribute.

Read more...

Improving Clinical Management for nAMD and DME

Global survey data identify barriers and opportunities.

Read more...